Circulating haptoglobin is an independent prognostic factor in the sera of patients with epithelial ovarian cancer.

OBJECTIVE This study was conducted to evaluate the prognostic significance of haptoglobin levels in the overall survival of patients presenting with various stages of epithelial ovarian cancer. MATERIALS AND METHODS We employed an in-house sandwich enzyme-linked immunosorbent assay method to determine the concentrations of preoperative haptoglobin and C-reactive protein (CRP) in sera samples obtained from 66 malignant tumors, 60 benign tumors, and 10 normal healthy women. RESULTS Levels of serum haptoglobin significantly correlated with tumor type (P < .001) and International Federation of Gynecology and Obstetrics stage (P < .05). A significant correlation was observed between clinical stage and patient survival (r = 5.99, P = .026). Our data also indicated that elevated serum haptoglobin levels were associated with poor outcome for overall survival using both univariate and multivariate analyses (P = .048 and P = .036 respectively). Using Pearson's correlation, we have noted that serum CRP concentrations significantly correlated with haptoglobin levels (r(2) = 0.22, P < .001). Immunohistochemical findings and Western blot analyses were compatible with sera levels of haptoglobin in which a higher intensity of staining occurred in late-stage epithelial ovarian cancers. CONCLUSION This study provides evidence that preoperative serum levels of haptoglobin could serve as an independent prognostic factor in patients presenting with epithelial ovarian cancer.

[1]  Osamu Ishikawa,et al.  Fucosylated haptoglobin is a novel marker for pancreatic cancer: A detailed analysis of the oligosaccharide structure and a possible mechanism for fucosylation , 2006, International journal of cancer.

[2]  T. Erlinger,et al.  C-reactive protein levels and subsequent cancer outcomes: results from a prospective cohort study. , 2006, European journal of cancer.

[3]  Nuzhat Ahmed,et al.  Proteomic tracking of serum protein isoforms as screening biomarkers of ovarian cancer , 2005, Proteomics.

[4]  Chundi He,et al.  Expression of haptoglobin in human keratinocytes and Langerhans cells , 2005, The British journal of dermatology.

[5]  G. Mantovani,et al.  Hemoglobin levels correlate with interleukin-6 levels in patients with advanced untreated epithelial ovarian cancer: role of inflammation in cancer-related anemia. , 2005, Blood.

[6]  Jilin Li,et al.  Proteomic analysis of blood level of proteins before and after operation in patients with esophageal squamous cell carcinoma at high-incidence area in Henan Province. , 2004, World journal of gastroenterology.

[7]  G. Rice,et al.  Proteomic-based identification of haptoglobin-1 precursor as a novel circulating biomarker of ovarian cancer , 2004, British Journal of Cancer.

[8]  S. Awadallah,et al.  Haptoglobin polymorphism in breast cancer patients form Jordan. , 2004, Clinica chimica acta; international journal of clinical chemistry.

[9]  S. Mao,et al.  Purification of human haptoglobin 1-1, 2-1, and 2-2 using monoclonal antibody affinity chromatography. , 2004, Protein expression and purification.

[10]  S. Gygi,et al.  Haptoglobin-α subunit as potential serum biomarker in ovarian cancer: Identification and characterization using proteomic profiling and mass spectrometry , 2003 .

[11]  G. Pasterkamp,et al.  Nitric oxide synthesis is involved in arterial haptoglobin expression after sustained flow changes , 2002, FEBS letters.

[12]  G. Rustin,et al.  Role of tumour markers in monitoring epithelial ovarian cancer , 2000, British Journal of Cancer.

[13]  J. Westermarck,et al.  Regulation of matrix metalloproteinase expression in tumor invasion , 1999, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[14]  L. Twiggs,et al.  Ascites levels of haptoglobin in patients with ovarian cancer , 1993, Cancer.

[15]  S. Thompson,et al.  Increased fucosylation and other carbohydrate changes in haptoglobin in ovarian cancer. , 1992, Cancer letters.

[16]  B. Cantwell,et al.  Parallel changes in the blood levels of abnormally-fucosylated haptoglobin and alpha 1,3 fucosyltransferase in relationship to tumour burden: more evidence for a disturbance of fucose metabolism in cancer. , 1992, Cancer letters.

[17]  B. Cantwell,et al.  Abnormally-fucosylated haptoglobin: a cancer marker for tumour burden but not gross liver metastasis. , 1991, British Journal of Cancer.

[18]  S. Ellenberg,et al.  Adjuvant therapy in stage I and stage II epithelial ovarian cancer. Results of two prospective randomized trials , 1990, The New England journal of medicine.

[19]  S. Thompson,et al.  Elevated levels of abnormally-fucosylated haptoglobins in cancer sera. , 1987, British Journal of Cancer.

[20]  J. Spinelli,et al.  Ovarian Carcinoma: A Multivariate Analysis of Prognostic Factors , 1985, Obstetrics and gynecology.

[21]  G. B. Petersen,et al.  A balanced translocation t(11;16)(q13;p11), a cytogenetic study and an attempt at gene localization , 1978, Human Genetics.

[22]  D. Faraggi,et al.  Haptoglobin-related protein as a serum marker in malignant lymphoma , 2008, Pathology & Oncology Research.

[23]  M. Salto‐Tellez,et al.  Reliability of Tissue Microarrays in Detecting Protein Expression and Gene Amplification in Breast Cancer , 2003, Modern Pathology.

[24]  S. Ng,et al.  Expression profiles of interleukin-15 in early and late gestational human placenta and in pre-eclamptic placenta. , 2001, Molecular human reproduction.

[25]  I. Kątnik-Prastowska,et al.  Serum haptoglobin, CA 125 and interleukin 6 levels in malignant and non-malignant tumors of the ovary. , 1999, Archivum Immunologiae et Therapiae Experimentalis.

[26]  J. Zuwała-Jagiełło,et al.  Acute phase reactants and circulating immune complexes in patients with ovarian carcinoma. , 1991, Archivum immunologiae et therapiae experimentalis.

[27]  R. J. Mitchell,et al.  Associations between the two serum proteins haptoglobin and transferrin and leukaemia. , 1988, Human heredity.

[28]  H. Hanssen,et al.  Distribution of alpha-1-antitrypsin and haptoglobin phenotypes in bladder cancer patients. , 1987, Human heredity.

[29]  G. Beckman,et al.  Haptoglobin groups and lung cancer. , 1986, Human heredity.

[30]  W. Dobryszycka,et al.  Clinical usefulness of serum acute-phase reactants in patients with ovarian tumors. , 1981, Neoplasma.

[31]  K. Jung,et al.  Transferrin, C3 complement, haptoglobin, plasminogen and alpha 2-microglobulin in patients with urogenital tumors. , 1980, European urology.